title: [Acetylsalicylic acid in the treatment of cardiovascular and cerebrovascular diseases].
abstract: This year acetylsalicylic acid (aspirin) celebrates its 100-year anniversary. While the drug was previously used mainly as an antipyretic and a pain-killer, aspirin has, during the last 10-15 years, become one of the most important agents in the treatment of cardiovascular and cerebrovascular diseases. In addition to being one of our oldest drugs, aspirin is one of the most interesting and widely used remedies. The antithrombotic property of aspirin is mainly related to its irreversible inhibition of the production of platelet-derived thromboxane A2, which possesses aggregatory and vasoconstrictive properties. Aspirin reduces the risk in patients with overt cardiovascular and cerebrovascular diseases, i.e. chronic stable and unstable angina pectoris. It also reduces the risk in the acute phase of and following a myocardial infarction and after a transient ischemic attack or stroke. The use of the drug is controversial in primary cardiovascular prevention. Overall mortality is not reduced, and side-effects, such as increased bleeding tendency, may be serious. This side-effect is dose-dependent, and smaller doses (75-160 mg) which have the same effect as higher doses should be preferred.
authors.affiliation: Institutt for farmakoterapi, Oslo.
authors.forename: K
authors.initials: K
authors.lastname: Landmark
mesh_terms: D001241:Aspirin / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
vernacular_title: Acetylsalisylsyre i behandlingen av kardiovaskulaere og cerebrovaskulaere sykdommer.